Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.1K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2015
Same author

Long-Acting Therapies Will Expand Growth Hormone Deficiency Market.

P & T : a peer-reviewed journal for formulary management·2015
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2015
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2015
Same author

Pharmaceutical Approval Update.

P & T : a peer-reviewed journal for formulary management·2015
Same author

Exciting Therapies Ahead in Prostate Cancer.

P & T : a peer-reviewed journal for formulary management·2015

Related Experiment Video

Updated: Apr 1, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K

Multiple Sclerosis: Progress, but No Cure.

Kunj Gohil

    P & T : a Peer-Reviewed Journal for Formulary Management
    |September 30, 2015
    PubMed
    Summary

    Approved agents treat symptoms and exacerbations, offering disease-modifying therapy. Future treatments primarily focus on managing relapsing forms of the disease.

    Area of Science:

    • Pharmacology
    • Clinical Therapeutics
    • Neurology

    Background:

    • Current therapeutic strategies address acute exacerbations and symptoms.
    • Existing treatments also offer disease-modifying effects.
    • A significant unmet need exists for managing progressive forms of the disease.

    Purpose of the Study:

    • To review current therapeutic agents for the disease.
    • To evaluate the landscape of emerging therapies.
    • To identify key areas for future drug development.

    Main Methods:

    • Literature review of approved and investigational agents.
    • Analysis of clinical trial data for efficacy and safety.
    • Assessment of treatment targets for different disease phenotypes.

    More Related Videos

    Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
    08:11

    Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

    Published on: November 14, 2016

    11.7K
    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
    08:51

    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

    Published on: February 19, 2021

    10.1K

    Related Experiment Videos

    Last Updated: Apr 1, 2026

    The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
    11:35

    The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

    Published on: June 30, 2014

    58.9K
    Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
    08:11

    Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

    Published on: November 14, 2016

    11.7K
    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
    08:51

    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

    Published on: February 19, 2021

    10.1K

    Main Results:

    • Approved agents are effective for symptom management and exacerbation treatment.
    • Most investigational therapies are designed for relapsing disease forms.
    • Limited options are currently available for non-relapsing or progressive disease.

    Conclusions:

    • Current therapies provide symptomatic relief and modify disease course.
    • The pipeline is heavily focused on relapsing-onset disease.
    • Further research is needed to develop treatments for progressive forms.